Cardiology Headline News

Semaglutide cut the risk for worsening heart failure and CV death for adults with HF with preserved ejection fraction, according to data presented at the European Society of Cardiology Congress and simultaneously published in The Lancet.

An AI-driven application reduced the time needed for documentation of patient visits, allowing providers more time for shared decision-making and communication with patients, a pilot study showed.

As part of the ongoing challenge to achieve work-life integration, experts are pursuing creative endeavors and practicing decompression to provide outlets for physicians struggling with burnout.

Halting oral anticoagulation during transcatheter aortic valve replacement was not noninferior to anticoagulant continuation, but conferred lower bleeding risk and had no impact on thromboembolic risk, a speaker reported.

In patients with coronary artery disease and severe aortic stenosis undergoing transcatheter aortic valve replacement, those who also had PCI had better outcomes than those who had their CAD managed conservatively, researchers reported.

Women with fetal overgrowth or hypertensive disorders of pregnancy have notable continuous glucose monitor-derived glycemic patterns detected during early pregnancy, sometimes without a gestational diabetes diagnosis, researchers reported.

Retirement planning for physicians is a critical aspect of financial management, given the unique challenges and opportunities they face.

A single combined measure of three modifiable biomarkers in healthy women at midlife was predictive of 30-year risk for future cardiovascular events, according to new research presented at the European Society of Cardiology Congress.

Treatment of atrial fibrillation with asundexian, a novel factor XIa inhibitor, was associated with increased stroke and systemic embolism risk despite lower bleeding risk compared with apixaban, a speaker reported.

In patients with HF and secondary mitral regurgitation, transcatheter edge-to-edge repair was noninferior to mitral valve surgery for efficacy and was linked with fewer safety endpoint events, according to data from the MATTERHORN trial.